First Time Loading...

Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 1.46 USD 2.1% Market Closed
Updated: Apr 29, 2024
Section:
 

Wall Street
Price Targets

SPRO Price Targets Summary
Spero Therapeutics Inc

Wall Street analysts forecast SPRO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.

SPRO Lowest Forecast
Wall Street Target
7.07 USD
384% Upside
SPRO Average Forecast
Wall Street Target
7.65 USD
424% Upside
SPRO Highest Forecast
Wall Street Target
8.4 USD
475% Upside
Lowest
Price Target
7.07 USD
384% Upside
Average
Price Target
7.65 USD
424% Upside
Highest
Price Target
8.4 USD
475% Upside
Spero Therapeutics Inc Competitors:
Price Targets
300149
ChemPartner PharmaTech Co Ltd
188% Upside
ZYME
Zymeworks Inc
84% Upside
FYB
Formycon AG
164% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
71% Upside
300149
ChemPartner PharmaTech Co Ltd
188% Upside
ZYME
Zymeworks Inc
84% Upside
FYB
Formycon AG
164% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
71% Upside
J
600201
Jinyu Bio-Technology Co Ltd
12% Upside
ABIO
ARCA Biopharma Inc
96% Upside
RXRX
Recursion Pharmaceuticals Inc
63% Upside
C
049960
Cell Biotech Co Ltd
380% Upside

Revenue
Forecast

Revenue Estimate
Spero Therapeutics Inc

For the last 7 years the compound annual growth rate for Spero Therapeutics Inc's revenue is 126%. The projected CAGR for the next 3 years is -18%.

126%
Past Growth
-18%
Estimated Growth
Estimates Accuracy
29%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Spero Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Spero Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-62%
Average Miss
What are analyst estimates?

See Also

Summary
SPRO intrinsic value, competitors valuation, and company profile.
DCF Valuation
SPRO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SPRO stock valuation using valuation multiples.
Wall Street Estimates
SPRO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SPRO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is SPRO's stock price target?
Price Target
7.65 USD

According to Wall Street analysts, the average 1-year price target for SPRO is 7.65 USD with a low forecast of 7.07 USD and a high forecast of 8.4 USD.

What is Spero Therapeutics Inc's Revenue forecast?
Projected CAGR
-18%

For the last 7 years the compound annual growth rate for Spero Therapeutics Inc's revenue is 126%. The projected CAGR for the next 3 years is -18%.

ALPHA SPREAD
Join more than 132,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.